Success Metrics

Clinical Success Rate

100.0%

Based on 9 completed trials

Completion Rate

100%(9/9)

Active Trials

0(0%)

Results Posted

89%(8 trials)

Phase Distribution

Ph not_applicable

10%

Ph phase_3

60%

Ph phase_2

10%

Ph phase_1

10%

Ph phase_4

10%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution10 total trials

Phase 1Safety & dosage

1(10.0%)

Phase 2Efficacy & side effects

1(10.0%)

Phase 3Large-scale testing

6(60.0%)

Phase 4Post-market surveillance

1(10.0%)

N/ANon-phased studies

1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(9)

Other(1)

Detailed Status

Completed9

Suspended1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 11 (10.0%)

Phase 21 (10.0%)

Phase 36 (60.0%)

Phase 41 (10.0%)

N/A1 (10.0%)

Trials by Status

completed990%

suspended110%

Recent Activity

0 active trials

Showing 5 of 10

suspendednot_applicable

Comparative Efficacy of Once-daily LAMA/LABA Combinations Versus Tiotropium on Constant-work-rate Cycle Endurance in COPD

NCT07541378

completedphase_4

Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

NCT01957150

completedphase_3

A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma

NCT02446418

completedphase_3

Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease

NCT01313676

completedphase_3

Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02105974

View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials

NCT07541378Not Applicable

Comparative Efficacy of Once-daily LAMA/LABA Combinations Versus Tiotropium on Constant-work-rate Cycle Endurance in COPD

Suspended

NCT01957150Phase 4

Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

Completed

NCT02446418Phase 3

A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma

Completed

NCT01313676Phase 3

Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease

Completed

NCT02105974Phase 3

Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed

NCT01181895Phase 3

Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma

Completed

NCT01336608Phase 3

A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD

Completed

NCT00625196Phase 1

Comparing Two Respiratory Drugs in Combination and Separately From a Novel Inhaler Device in Healthy Japanese Subjects

Completed

NCT01573767Phase 2

Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children